Biogen (BIIB) Short-term Investments (2009 - 2026)

Biogen has reported Short-term Investments for 17 years, with the latest figure at $900.0 million in Q1 2026.

• On a quarterly basis, Short-term Investments changed N/A year-over-year to $900.0 million in Q1 2026; TTM through Mar 2026 was $900.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $807.2 million, changed N/A from the prior year.
• Short-term Investments was $900.0 million for Q1 2026 at Biogen, up from $807.2 million in the prior quarter.
• The five-year high for Short-term Investments was $3.5 billion in Q2 2023, with the low at $97.6 million in Q3 2025.
• Average Short-term Investments over 4 years is $1.6 billion, with a median of $1.5 billion recorded in 2022.
• The largest YoY upside for Short-term Investments was 64.37% in 2022 against a maximum downside of 12.58% in 2022.
• Over 4 years, Short-term Investments stood at $1.5 billion in 2022, then soared by 134.85% to $3.5 billion in 2023, then tumbled by 76.67% to $807.2 million in 2025, then grew by 11.5% to $900.0 million in 2026.
• The last three Short-term Investments figures came in at $900.0 million (Q1 2026), $807.2 million (Q4 2025), and $97.6 million (Q3 2025), per Business Quant data.